Phase I

25% of our clinical trials were Phase I trials. Since more than 30 years we design drug development programs  exactly to the needs of our clients. Our services include strategic considerations, medical  writing, statistical planning, study conduct, project management, monitoring and more. Our large scientific network of connects you with opinion leaders, investigators and international experts  with a special focus on neurodegenerative diseases or other indications as needed. Throughout Central and Eastern European Countries our investigator network provides you access to your targeted patient population or special population groups. In addition we offer access to Phase I units which are able to meet your requirements. The Neuroscios specialists are familiar with regulatory procedures in Central and Eastern European Countries.

As safety is the primary endpoint of a Phase I clinical trial you would like to have the strong pharmacovigilance team of NeuroScios. In addition Neuroscios is able to set up a Data and Safety Monitoring Board (DSMB) to ensure periodic medical review and ensure subject safety - and guarantees you the opinion of true experts.